Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP065: Less anti-infliximab antibody formation in paediatric Crohns patients on concomitant immunomodulatorsECCO '16 Amsterdam
Year: 2016
Authors:

H. Kansen1, P. van Rheenen2, R. Houwen1, W. Tjon A Ten3, G. Damen4, A. Kindermann5, J. Escher6, V. Wolters*1

1University Medical Centre-Wilhelmina Children’s Hospital, Department of Paediatric Gastroenterology, Utrecht, Netherlands, 2University of Groningen, University Medical Centre Groningen, Department of Paediatric Gastroenterology, Groningen, Netherlands, 3Maxima Medical Centre, Department of Paediatric Gastroenterology, Veldhoven, Netherlands, 4Radboud University Medical Centre-Amalia Children’s Hospital, Department of Paediatric Gastroenterology, Nijmegen, Netherlands, 5Emma Children´s Hospital, Academic Medical Centre, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 6, Erasmus Medical Centre-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands

DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

A. Strik*1, G. van den Brink1, C. Ponsioen1, R. Mathot2, M. Löwenberg1, G. D’Haens1

1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Hospital Pharmacy, Amsterdam, Netherlands

DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centreECCO '16 Amsterdam
Year: 2016
Authors:

J. Digby-Bell*1, B. Warner1, E. Johnston1, N. Unsworth2, Z. Arkir2, J. Sanderson1, P. Irving1

1Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Reference Chemistry, Biomedical Sciences, Viapath, London, United Kingdom

DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBDECCO '16 Amsterdam
Year: 2016
Authors:

J. F. Brandse*1, D. R. Mould2, Y. K. Ashruf1, O. Smeekes1, S. Kuin1, A. Strik1, G.R. van den Brink1, G. R. D’Haens1

1Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, Netherlands, 2Projections Research Inc, Projections Research Inc, Phoenixville, Pennsylvania, United States

DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustmentECCO '16 Amsterdam
Year: 2016
Authors:

P. Harrow*1, C. Skinner1, T. Hoque1, A. Ibarra1, J. Lindsay1, 2

1Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom, 2Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom

DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1ECCO '16 Amsterdam
Year: 2016
Authors:

X. Roblin*1, M.T. Osterman2, S. Glover3, U. Navaneethan4, M. A. Popa5, T. Wyant6, A. James7, K. Lasch5, M. Rosario6

1CHU de Saint-Etienne, Saint-Etienne, France, 2Hospital of the University of Pennsylvania and the Presbyterian Medical Centre of Philadelphia, Philadelphia, Pennsylvania, United States, 3Southeastern Centre for Inflammatory Bowel Diseases/Affiliate Faculty Biomedical Engineering, University of Florida, Gastroenterology, Hepatology, and Nutrition, Gainesville, Florida, United States, 4Centre for Interventional Endoscopy, Florida Hospital, Orlando, Florida, United States, 5Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States, 6Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, United States, 7Takeda Development Centre Europe Ltd, London, United Kingdom

DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studiesECCO '16 Amsterdam
Year: 2016
Authors:

A. Mukherjee1, S. Tsuchiwata2, C. Deng3, C. Vong4, R. Xie3, S.W. Martin4, D. Yu5, D. Woodworth5, W. Niezychowski5, C. Su*5

1Pfizer Inc, Groton, United States, 2Pfizer Japan Inc, Tokyo, Japan, 3Pfizer Inc, Shanghai, China, 4Pfizer Inc, Cambridge, United States, 5Pfizer Inc, Collegeville, Pennsylvania, United States

DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomesECCO '16 Amsterdam
Year: 2016
Authors:

R. Battat1, U. Kopylov*2, T. Bessissow1, A. Bitton1, A. Cohen3, M. Martel1, E. G. Seidman4, W. Afif4

1McGill University Health Centre, Gastroenterology, Montreal, Canada, 2Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, 3Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, 4McGill University, Division of Gastroenterology, Montreal Quebec, Canada

DOP073: Incidental diagnosis of inflammatory bowel disease through bowel cancer screening: a 7-year experienceU. Nosegbe*1, J. A. Scott1, R. O. Butcher1, 2, A. M. Abbasi1, R. C. Prudham1, R. George1, J. Limdi1, 2ECCO '16 Amsterdam
Year: 2016
Authors:

1The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 2University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Background: The UK Bowel Cancer Screening programme (BCSP) was launched in 2006 in England and following an age-extension, now screens individuals aged 60–74 years with a faecal occult blood test (FOBt) followed by screening colonoscopy if FOBt positive. We reported at ECCO 2012 the world’s first experience of incidental diagnosis of IBD through screening and now present an experience of incidental IBD over 7-years at our centre.

DOP074: Incidence and prediction of fistula formation in EnglandECCO '16 Amsterdam
Year: 2016
Authors:

K. Sahnan*1, A. Askari1, S. Adegbola*1, P. Tozer1, R. Phillips1, A. Hart2, O. Faiz1

1St Mark’s Hospital, Colorectal Surgery, London, United Kingdom, 2St Mark’s Hospital, IBD/Physiology, London, United Kingdom

DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panelECCO '16 Amsterdam
Year: 2016
Authors:

C. Siegel1, C. Whitman2, B. Spiegel2, B. Feagan3, B. Sands4, E. Loftus5, R. Panaccione6, G. D’Haens7, C. Bernstein8, R. Gearry9, S. Ng10, G. Mantzaris11, B. Sartor12, M. Silverberg13, R. Riddell13, I. Koutroubakis14, C. O’Morain15, P. Lakatos16, D. McGovern2, J. Halfvarson17, W. Reinisch18, G. Rogler19, W. Kruis20, C. Tysk17, S. Schreiber21, S. Danese22, W. Sandborn23, A. Griffiths24, B. Moum25, C. Gasche26, F. Pallone27, S. Travis28, J. Panes29, J.-F. Colombel4, S. Hanauer30, L. Peyrin-Biroulet*31

1Geisel School of Medicine at Dartmouth, Inflammatory Bowel Disease Centre, Lebanon, New Hampshire, United States, 2Cedars-Sinai Medical Centre, Los Angeles, California, United States, 3Roberts Clinical Trials, London, Ontario, Canada, 4Icahn School of Medicine at Mount Sinai, New York, New York, United States, 5Mayo Clinic, Rochester, Minnesota, United States, 6University of Calgary, Calgary, Canada, 7Academic Medical Centre, Amsterdam, Netherlands, 8University of Manitoba, Winnipeg, Canada, 9University of Otago, Christchurch, New Zealand, 10Chinese University of Hong Kong, Hong Kong, Hong Kong, 11Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece, 12University of North Carolina, Chapel Hill, North Carolina, United States, 13Mount Sinai Hospital, Toronto, Canada, 14University Hospital Heraklion, Crete, Greece, 15Charlemont Clinic, Dublin, Ireland, 16Semmelweis University, Budapest, Hungary, 17Örebro University, Örebro, Sweden, 18McMaster University Medical Centre, Department of Gastroenterology, Hamilton, Canada, 19University Hospital Zürich, Clinic for Hepatology and Gastroenterology, Zürich, Switzerland, 20University of Cologne, Clinic for Internal Medicine, Koln, Germany, 21Universitätsklinikum Schleswig-Holstein Kiel, Clinic for Internal Medicine, Kiel, Germany, 22Humanitas University, Milan, Italy, 23University of California San Diego, San Diego, California, United States, 24Hospital for Sick Children, Toronto, Canada, 25Oslo University, Oslo, Norway, 26Medical University and General Hospital Vienna, Vienna, Austria, 27University Rome, Rome, Italy, 28Oxford University Hospital, Oxford, United Kingdom, 29Hospital Clinic de Barcelona, Barcelona, Spain, 30Northwestern Feinberg School of Medicine, Chicago, Illinois, United States, 31CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France

DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.ECCO '16 Amsterdam
Year: 2016
Authors:

M. Halling1, T. Knudsen2, J. Kjeldsen1, J. Nielsen3, L. Koch Hansen*4

1Odense University Hospital, Department of Gastroenterology, Odense, Denmark, 2Esbjerg Hospital, Dept. of Gastroenterology and Hepatology, Esbjerg, Denmark, 3Odense University Hospital, Department of Clinical Epidemiology, Odense, Denmark, 4Vejle Hospital, Dept. of Gastroenterology and Hepatology, Vejle, Denmark

DOP077: Immunochip analysis identifies multiple susceptibility loci for collagenous colitisECCO '16 Amsterdam
Year: 2016
Authors:

G. Roda*1, H. Jianzhong2, Z. Zhongyang3, J. Torres1, A. Chen4, R. Petras5, D. Pardi6, A. Juga7, G. Levi3, W. Cao8, F. Rieder9, I. Gordon10, K. Hao3, N. Harpaz11, J. Cho12, J.-F. Colombel12, I. Peter3

1Icahn School of Medicine, Gastroenterology, New York, New York, United States, 2Icahn School of Medicine, New York, New York, United States, 3Icahn School of Medicine at Mount Sinai, Medicine, New York, New York, United States, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, New York, United States, 5Ameripath, Pathology, Cleveland, Ohio, United States, 6Mayo Clinic, Gastroenterology, Rochester, Minnesota, United States, 7New York-Presbyterian, Pathology, New York, New York, United States, 8University of Rochester, Pathology, Rochester, Minnesota, United States, 9University of Cleveland, Gastroenterology, Cleveland, Ohio, United States, 10Cleveland Clinic, Department of Anatomic Pathology, Cleveland, Ohio, United States, 11Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, New York, United States, 12Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States

DOP078: Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryECCO '16 Amsterdam
Year: 2016
Authors:

M. Dubinsky1, J. Hyams2, R. Baldassano3, R. Colletti4, S. Cucchiara5, J. Escher6, W. Faubion7, J. Fell8, B. Gold9, A. Griffiths10, S. Koletzko11, S. Kugathasan12, J. Markowitz13, F. Ruemmele14, G. Veerman*15, H. Winter16, N. Masel17, K. Tang18, M. Thayu18

1Mount Sinai, Icahn School of Medicine, New York, New York, United States, 2Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 3The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 4University of Vermont Children’s Hospital, Burlington, Vermont, United States, 5Sapienza University of Rome/University Hospital, Rome, Italy, 6Erasmus Mc-Sophia Children’s Hospital, Rotterdam, Netherlands, 7Mayo Clinic, Rochester, Minnesota, United States, 8Chelsea and Westminster Hospital, London, United Kingdom, 9Children’s Centre for Digestive Health Care, Atlanta, Georgia, United States, 10Hospital for Sick Children, University of Toronto, Department of Paediatrics, Toronto, Canada, 11Ludwig Maximilians Universität München, Munich, Germany, 12Emory University, Atlanta, Georgia, United States, 13Cohen Children’s Medical Centre Of New York, New York, New York, United States, 14Hôpital Necker-Enfants Malades, Paris, France, 15Universitair Ziekenhaus, Brussels, Belgium, 16Mass General Hospital for Children, Boston, Massachusetts, United States, 17DOCS, Durham, North Carolina, United States, 18Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

DOP079: Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillanceECCO '16 Amsterdam
Year: 2016
Authors:

J. Kirchgesner*1, M. Svrcek2, C. Landman1, A. Bourrier1, 
I. Nion-Larmurier1, H. Sokol1, J. Cosnes1, J.-F. Flejou2, L. Beaugerie1

1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, 2Saint-Antoine Hospital, AP-HP, Pathology, Paris, France

DOP080: Final results of a randomised study comparing high-definition colonoscopy alone with high- definition dye spraying and electronic virtual chromoendoscopy using iSCAN for detection of colonic neoplastic lesions during IBD surveillance colonoscopyECCO '16 Amsterdam
Year: 2016
Authors:

M. Iacucci*1, M. Fort Gasia1, A. Oluseyi1, R. Panaccione1, S. Gui X2, S. Urbanski3, P. Minoo3, S. Ghosh1

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Pathology, Calgary, Canada, 3University of Calgary, Calgary, Canada

DOP081: Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centreECCO '16 Amsterdam
Year: 2016
Authors:

D. Rubin*, N. Krugliak Cleveland, D. Rodriquez

University of Chicago Medicine, Inflammatory Bowel Disease Centre, Chicago, Illinois, United States

DOP082: Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character ConsortiumECCO '16 Amsterdam
Year: 2016
Authors:

R. Kalla*1, A. Ocklind2, C. Petrén2, N. Nordberg2, N. Kennedy1, N. Ventham1, E. Pettersson2, D. Bergemalm3, J. Lindström4, S. Vatn4, H. Hjortswang5, E. Nimmo1, H. Drummond1, P. Ricanek6, F. Dahl4, D. Wilson1, J. Jahnsen4, F. Gomollón7, M. Pierik8, J. Söderholm9, M. Vatn4, J. Halfvarson3, IBD Character Consortium1, J. Satsangi1

1University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 2Olink, Bioscience, Uppsala, Sweden, 3Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 4Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 5Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden, 6Akershus University Hospital, Deaprtment of Gastroenterology, Lorenskog, Norway, 7University of Zaragosa, Gastroenterology, Zaragosa, Spain, 8Maastricht University Medical Centre (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 9Linköping University Hospital, Department of Surgery, Linköping, Sweden

DOP083: Faecal calprotectin improves the predictive power of 3 practical indices for mucosal healing amongst patients with Crohn’s disease: results from PREDICTECCO '16 Amsterdam
Year: 2016
Authors:

W. Sandborn*1, R. Panaccione2, J.-F. Colombel3, E. Louis4, A. Robinson5, K. Wallace5, M. Bereswill6, M. Shapiro5, N. Chen5, M. Skup5, S. Wang5, R. Thakkar5, J. Chao5

1University of California, San Diego, La Jolla, California, United States, 2University of Calgary, Medicine, Calgary, Canada, 3Centre Hospitalier Universitaire de Lille, Lille, France, 4University of Liège, Liège, Belgium, 5AbbVie Inc., North Chicago, Illinois, United States, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

DOP084: Identification of a potential new prognostic biomarker to select inflammatory bowel disease patients that fail standard therapyECCO '16 Amsterdam
Year: 2016
Authors:

M. S. Pereira1, S. Campos1, A. M. Dias1, I. Pedroto2, C. A. Reis1, 3, L. Maia2, R. Marcos-Pinto2, 3, P. Lago2, S. S. Pinho*1, 3

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & Institute for Research and Innovation in Health (i3S), Porto, Portugal, 2Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, 3Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal